This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahon, F.-X. Articles by Pasquet, J.-M. Search for Related Content PubMed PubMed Citation Articles by Mahon, F.-X. Articles by Pasquet, J.-M.

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

¹ Hématopoïèse Leucémique et Cible Thérapeutique, INSERM U876, Université Victor Ségalen, Laboratoire d'hématologie CHU de Bordeaux, Bordeaux cedex, France; ² Laboratoire d'Hématologie et de Cytogénétique, Centre Hospitalier Lyon Sud, Pierre Bénite, France Hematology Department, Hôpital Edouard Herriot, Lyon cedex, France; ³ Novartis Pharma AG, Basel, Switzerland; and ⁴ CNRS UMR5237, Centre de Recherche de Biochimie Macromoléculaire, Montpellier, France

Requests for reprints: Jean-Max Pasquet, Hématopoïèse leucémique et cible thérapeutique, INSERM U876, Université Victor Ségalen, 146 rue Léo Saignat Bat TP 4^e étage, 33076 Bordeaux cedex, France. Phone: 33-55757-4547; Fax: 33-55693-8883; E-mail: jean-max.pasquet{at}umr5533.u-bordeaux2.fr.

Key Words: chronic myeloid leukemia • drug resistance • BCR-ABL • tyrosine kinase inhibitors

Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl–positive acute lymphoblastic leukemia. Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease. In the current study, we generated nilotinib-resistant cell lines and investigated their mechanism of resistance. Overexpression of BCR-ABL and multidrug resistance gene (MDR-1) were found among the investigated mechanisms. We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding. Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib. Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML. Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity. In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn. Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance. [Cancer Res 2008;68(23):9809–16]

This article has been cited by other articles:

				J. S. Lagas, R. A.B. van Waterschoot, R. W. Sparidans, E. Wagenaar, J. H. Beijnen, and A. H. Schinkel Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation Mol. Cancer Ther., February 1, 2010; 9(2): 319 - 326. [Abstract] [Full Text] [PDF]

				D. Milojkovic and J. Apperley Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2009; 15(24): 7519 - 7527. [Abstract] [Full Text] [PDF]

				T. Hughes, G. Saglio, S. Branford, S. Soverini, D.-W. Kim, M. C. Muller, G. Martinelli, J. Cortes, L. Beppu, E. Gottardi, et al. Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase J. Clin. Oncol., September 1, 2009; 27(25): 4204 - 4210. [Abstract] [Full Text] [PDF]

				S. Grosso, A. Puissant, M. Dufies, P. Colosetti, A. Jacquel, K. Lebrigand, P. Barbry, M. Deckert, J. P. Cassuto, B. Mari, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors Mol. Cancer Ther., July 1, 2009; 8(7): 1924 - 1933. [Abstract] [Full Text] [PDF]

				D. Bixby and M. Talpaz Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance Hematology, January 1, 2009; 2009(1): 461 - 476. [Abstract] [Full Text] [PDF]